Preparation ACOMPLIA® of 20 mg has passed tests of safety with participation over 6300 patients. In platsebo-supervised researches frequency of cancellation of a preparation because of undesirable reactions was 15,7 % in the group receiving ACOMPLIA®. Read more…
Action of preparation ACOMPLIA® is based on selective blockade CB1 of the receptors localised in a brain both peripheral bodies and playing an important role in an exchange of fats, Read more…
Preparation ACOMPLIA® of 20 mg is intended for decrease plural risk factors at patients with adiposity and excess weight. Read more…
